Cancer Metastasis: A Therapeutic Target
1China Medical University, Taichung, Taiwan
2Tunghai University, Taichung, Taiwan
3Central University of Tamil Nadu, Tamil Nadu, India
4University of California, Oakland, USA
5University of Texas, Austin, USA
Cancer Metastasis: A Therapeutic Target
Description
This special issue aims to publish articles covering the broader research area of cancer metastasis and will be an invaluable resource for anyone working in the field of cancer and interested in cancer metastasis. Metastasis to vital organs from cancers of breast, lung, liver, colon, melanoma, and prostate is responsible for 90% of all cancer deaths. Patients diagnosed with metastatic disease have an extremely poor prognosis, with a 10-year survival rate of only 5–10%. This special issue would discuss the cancer metastasis. Clinical and translational advances pertaining to the metastatic process may be thwarted by our poor understanding of the molecular and biochemical mechanisms involved in the process of metastasis. Metastasis is a complex multistep sequential process involving invasion of cancer cells, intravasation, circulation, arrest in the capillary bed of secondary organ, and colonization at the secondary site. Experimental studies have shown that, among all the cancer cells injected into the circulation, very few have the capacity to successfully metastasize to a distant organ. This inefficiency in metastatic ability has been attributed to crucial rate-limiting steps of metastasis specifically the host immune system in the circulation, extravasation, and postextravasation survival in colonization. Cells that metastasize to secondary sites may not necessarily proliferate immediately and could remain dormant for a long period until the microenvironment at the secondary site becomes congenial for its proliferation. The mechanisms underlying the metastatic spread of cancer, including the orchestrated programs coordinating cell migration and dissemination throughout disease progression, remain unclear.
Therefore, the main aim and scope of this special issue are to discuss the various factors including adhesion proteins/EMT/target therapy that specifically affect metastasis, metastasis suppressor, or metastasis promoters; it would provide insights into the molecular mechanisms of metastasis and could launch clinical translational initiatives. A deeper understanding of the molecular concepts and processes involved in metastasis may pave the way toward new prognostic models and ways of planning treatment.
We especially welcome original research papers (in vitro, in vivo, or phase II trials) or systematic or meta-analytic reviews addressing unique technological advances to treat the cancer metastasis by using targeted therapy and well-being of cancer patients after primary treatment in the below mentioned areas. All submitted manuscripts will undergo rigorous peer review to assess their suitability for publication. This special issue is open for a very limited number of articles, which preferably describe and report significant advancement in the current state of the art in the above-mentioned areas.
Potential topics include but are not limited to the following:
- Hallmarks of cancer metastasis
- Epithelial-mesenchymal transition in cancer metastasis: mechanism and its clinical importance
- Cancer metastasis treatment using target therapy
- Suppression of signal transducer to inhibit growth of metastasis